- Home
- FUSB vs IFRX Comparison
FUSB vs IFRX Comparison
Compare FUSB & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSB
- IFRX
- Stock Information
- Founded
- FUSB 1952
- IFRX 2007
- Country
- FUSB United States
- IFRX Germany
- Employees
- FUSB N/A
- IFRX N/A
- Industry
- FUSB Major Banks
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- FUSB Finance
- IFRX Health Care
- Exchange
- FUSB Nasdaq
- IFRX Nasdaq
- Market Cap
- FUSB 72.6M
- IFRX 65.8M
- IPO Year
- FUSB N/A
- IFRX 2017
- Fundamental
- Price
- FUSB $12.85
- IFRX $0.79
- Analyst Decision
- FUSB
- IFRX Strong Buy
- Analyst Count
- FUSB 0
- IFRX 4
- Target Price
- FUSB N/A
- IFRX $7.75
- AVG Volume (30 Days)
- FUSB 2.3K
- IFRX 875.8K
- Earning Date
- FUSB 07-23-2025
- IFRX 08-07-2025
- Dividend Yield
- FUSB 2.20%
- IFRX N/A
- EPS Growth
- FUSB N/A
- IFRX N/A
- EPS
- FUSB 1.28
- IFRX N/A
- Revenue
- FUSB $38,449,000.00
- IFRX $140,242.00
- Revenue This Year
- FUSB N/A
- IFRX N/A
- Revenue Next Year
- FUSB N/A
- IFRX $6,309.47
- P/E Ratio
- FUSB $9.95
- IFRX N/A
- Revenue Growth
- FUSB N/A
- IFRX 30.90
- 52 Week Low
- FUSB $8.75
- IFRX $0.71
- 52 Week High
- FUSB $14.30
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- FUSB 65.47
- IFRX 34.33
- Support Level
- FUSB $12.46
- IFRX $0.75
- Resistance Level
- FUSB $12.75
- IFRX $0.83
- Average True Range (ATR)
- FUSB 0.10
- IFRX 0.05
- MACD
- FUSB 0.05
- IFRX -0.00
- Stochastic Oscillator
- FUSB 100.00
- IFRX 29.85
About FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.